DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Clinical trials for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS trials appear
Sign up with your email to follow new studies for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial aims to slow lung scarring in rare autoimmune disease
Disease control OngoingThis study is testing whether an investigational drug called tulisokibart can safely slow the progression of lung scarring in people with systemic sclerosis, a rare autoimmune disease. The trial involves 154 participants who will receive either the drug or a placebo for 50 weeks …
Matched conditions: DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Phase: PHASE2 • Sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Experimental cell therapy aims to tame severe, untreatable autoimmune diseases
Disease control OngoingThis early-stage study is testing a new cell therapy called CNTY-101 in people with severe autoimmune diseases like lupus, lupus nephritis, and scleroderma that have not improved with other treatments. The main goals are to find a safe dose and see if the therapy helps control th…
Matched conditions: DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Phase: PHASE1 • Sponsor: Century Therapeutics, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Scientists test 'Living Drug' to reset the immune system in devastating autoimmune conditions
Disease control OngoingThis early-stage study is testing the safety and initial effects of a personalized cell therapy called KYV-101 in adults with severe autoimmune diseases. The therapy involves collecting a patient's own immune cells, modifying them to target harmful B cells, and reinfusing them. U…
Matched conditions: DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Phase: PHASE1 • Sponsor: David Porter • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC